Vitamin D: A Bridge Between Kidney and Heart

Overview

Journal Life (Basel)

Specialty Biology

Date 2024 May 25

PMID 38792638

Authors

Carmine Secondulfo

Valeria Visco

Nicola Virtuoso

Martino Fortunato

Serena Migliarino

Antonella Rispoli

Lucia La Mura

Adolfo Stellato

Giuseppe Caliendo

Emanuela Settembre

Fabiana Galluccio

Sarah Hamzeh

Giancarlo Bilancio

Affiliations

Soon will be listed here.

Abstract

Chronic kidney disease (CKD) and cardiovascular disease (CVD) are highly prevalent conditions, each significantly contributing to the global burden of morbidity and mortality. CVD and CKD share a great number of common risk factors, such as hypertension, diabetes, obesity, and smoking, among others. Their relationship extends beyond these factors, encompassing intricate interplay between the two systems. Within this complex network of pathophysiological processes, vitamin D has emerged as a potential linchpin, exerting influence over diverse physiological pathways implicated in both CKD and CVD. In recent years, scientific exploration has unveiled a close connection between these two prevalent conditions and vitamin D, a crucial hormone traditionally recognized for its role in bone health. This article aims to provide an extensive review of vitamin D's multifaceted and expanding actions concerning its involvement in CKD and CVD.

References

Gois P, Wolley M, Ranganathan D, Seguro A . Vitamin D Deficiency in Chronic Kidney Disease: Recent Evidence and Controversies. Int J Environ Res Public Health. 2018; 15(8). PMC: 6121405. DOI: 10.3390/ijerph15081773. View

Wu-Wong J, Noonan W, Nakane M, Brooks K, Segreti J, Polakowski J . Vitamin d receptor activation mitigates the impact of uremia on endothelial function in the 5/6 nephrectomized rats. Int J Endocrinol. 2010; 2010:625852. PMC: 2821638. DOI: 10.1155/2010/625852. View

Wood D . Established and emerging cardiovascular risk factors. Am Heart J. 2001; 141(2 Suppl):S49-57. DOI: 10.1067/mhj.2001.109951. View

Qayyum F, Landex N, Agner B, Rasmussen M, Jons C, Dixen U . Vitamin D deficiency is unrelated to type of atrial fibrillation and its complications. Dan Med J. 2012; 59(9):A4505. View

Sattar N, Welsh P, Panarelli M, Forouhi N . Increasing requests for vitamin D measurement: costly, confusing, and without credibility. Lancet. 2012; 379(9811):95-6. DOI: 10.1016/S0140-6736(11)61816-3. View

Izzo C, Secondulfo C, Bilancio G, Visco V, Virtuoso N, Migliarino S . Chronic Kidney Disease with Mineral Bone Disorder and Vascular Calcification: An Overview. Life (Basel). 2024; 14(3). PMC: 10971621. DOI: 10.3390/life14030418. View

Cirillo M, Bilancio G, Guarino E, Cavallo P, Lombardi C, Costanzo S . Vitamin D Status and Indices of Mineral Homeostasis in the Population: Differences Between 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D. Nutrients. 2019; 11(8). PMC: 6722609. DOI: 10.3390/nu11081777. View

Farrell C, Martin S, McWhinney B, Straub I, Williams P, Herrmann M . State-of-the-art vitamin D assays: a comparison of automated immunoassays with liquid chromatography-tandem mass spectrometry methods. Clin Chem. 2012; 58(3):531-42. DOI: 10.1373/clinchem.2011.172155. View

Dao H, Essalihi R, Bouvet C, Moreau P . Evolution and modulation of age-related medial elastocalcinosis: impact on large artery stiffness and isolated systolic hypertension. Cardiovasc Res. 2005; 66(2):307-17. DOI: 10.1016/j.cardiores.2005.01.012. View

10.

Perez-Gomez M, Ortiz-Arduan A, Lorenzo-Sellares V . Vitamin D and proteinuria: a critical review of molecular bases and clinical experience. Nefrologia. 2013; 33(5):716-26. DOI: 10.3265/Nefrologia.pre2013.Apr.12025. View

11.

Li Y, Kong J, Wei M, Chen Z, Liu S, Cao L . 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002; 110(2):229-38. PMC: 151055. DOI: 10.1172/JCI15219. View

12.

Zhou S, Glowacki J . Chronic kidney disease and vitamin D metabolism in human bone marrow-derived MSCs. Ann N Y Acad Sci. 2017; 1402(1):43-55. PMC: 5659722. DOI: 10.1111/nyas.13464. View

13.

Matsushita K, Ballew S, Yee-Moon Wang A, Kalyesubula R, Schaeffner E, Agarwal R . Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease. Nat Rev Nephrol. 2022; 18(11):696-707. DOI: 10.1038/s41581-022-00616-6. View

14.

Kimura Y, Kawamura M, Owada M, Oshima T, MUROOKA M, Fujiwara T . Effectiveness of 1,25-dihydroxyvitamin D supplementation on blood pressure reduction in a pseudohypoparathyroidism patient with high renin activity. Intern Med. 1999; 38(1):31-5. DOI: 10.2169/internalmedicine.38.31. View

15.

Cunningham J, Locatelli F, Rodriguez M . Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011; 6(4):913-21. DOI: 10.2215/CJN.06040710. View

16.

Campanile A, Visco V, De Carlo S, Ferruzzi G, Mancusi C, Izzo C . Sacubitril/Valsartan vs. Standard Medical Therapy on Exercise Capacity in HFrEF Patients. Life (Basel). 2023; 13(5). PMC: 10220971. DOI: 10.3390/life13051174. View

17.

Naylor K, McArthur E, Leslie W, Fraser L, Jamal S, Cadarette S . The three-year incidence of fracture in chronic kidney disease. Kidney Int. 2014; 86(4):810-8. DOI: 10.1038/ki.2013.547. View

18.

Tentori F, Hunt W, Stidley C, Rohrscheib M, Bedrick E, Meyer K . Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int. 2006; 70(10):1858-65. DOI: 10.1038/sj.ki.5001868. View

19.

. Summary of Recommendation Statements. Kidney Int Suppl (2011). 2015; 3(1):5-14. PMC: 4284512. DOI: 10.1038/kisup.2012.77. View

20.

Reiss A, Miyawaki N, Moon J, Kasselman L, Voloshyna I, DAvino Jr R . CKD, arterial calcification, atherosclerosis and bone health: Inter-relationships and controversies. Atherosclerosis. 2018; 278:49-59. DOI: 10.1016/j.atherosclerosis.2018.08.046. View